Differential impact of radiation therapy after radical prostatectomy on recurrence patterns: an assessment using [⁶⁸Ga]Ga-PSMA ligand PET/CT(MRI)

Uro-Oncology

Use of <sup>68</sup> Ga-PSMA PET for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature

BJU Int.

Luiting HB, van Leeuwen PJ, Busstra MB, Brabander T, van der Poel HG, Donswijk ML, Vis AN, Emmett L, Stricker P, Roobol MJ

doi: 10.1111/bju.14944.

RECOMMENDED

Uro-Oncology

¹⁸F-fluciclovine PET-CT and ⁶⁸Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial

Lancet Oncol.

Calais J, Ceci F, Eiber M, Hope TA, Hofman MS, Rischpler C, Bach-Gansmo T, Nanni C, Savir-Baruch B, Elashoff D, Grogan T, Dahlbom M, Slavik R, Gartmann J, Nguyen K, Lok V, Jadvar H, Kishan AU, Rettig MB, Reiter RE, Fendler WP, Czernin J

doi: 10.1016/S1470-2045(19)30415-2.

Uro-Oncology

Response assessment using [⁶⁸Ga]Ga-PSMA ligand PET in patients undergoing systemic therapy for metastatic castration-resistant prostate cancer

Prostate.

Grubmüller B, Rasul S, Baltzer P, Fajkovic H, D'Andrea D, Berndl F, Maj-Hes A, Grubmüller KH, Mitterhauser M, Wadsak W, Pfaff S, Shariat SF, Hacker M, Kramer G, Hartenbach M

doi: 10.1002/pros.23919.

Uro-Oncology

The Optimal Timing for PSMA PET/CT in Patients with Biochemical Recurrence After Radical Prostatectomy

J Urol.

Luiting HB, van Leeuwen PJ, Remmers S, Donswijk M, Busstra MB, Bakker IL, Brabander T, Stokkel M, van der Poel HG, Roobol MJ

doi: 10.1097/JU.0000000000001012.

Uro-Oncology

PRIMARY Trial - A prospective multi-centre cross-sectional study of the additive diagnostic value of gallium-68 prostate specific membrane antigen (PSMA) PET/CT to multiparametric (mp) MRI in the diagnostic setting for men being investigated for prostate cancer: clinical trial protocol

BJU Int.

Amin A, Blazevski A, Thompson J, Scheltema MJ, Hofman MS, Murphy D, Lawrentschuk N, Sathianathen N, Kapoor J, Woo HH, Chalasani V, Rasiah K, van Leeuwen PJ, Tang R, Cusick T, Stricker P, Emmett L

doi: 10.1111/bju.14999.

Uro-Oncology

Preliminary results of a ⁶⁸ Ga-PSMA PET/CT prospective study in prostate cancer patients with occult recurrence: Diagnostic performance and impact on therapeutic decision-making

Prostate.

Rousseau C, Le Thiec M, Ferrer L, Rusu D, Rauscher A, Maucherat B, Frindel M, Baumgartner P, Fleury V, Denis A, Morel A, Varmenot N, Debeaupuis E, Campion L, Kraeber-Bodéré F

doi: 10.1002/pros.23869.

Uro-Oncology

⁶⁸Ga-PSMA-11 PET Detects Residual Prostate Cancer after Prostatectomy in a Multicenter Retrospective Study

J Urol.

Farolfi A, Gafita A, Calais J, Eiber M, Afshar-Oromieh A, Spohn F, Barbato F, Weber M, Ilhan H, Cervati V, Wetter A, Hadaschik B, Briganti A, Walz J, Pianori D, Fanti S, Haberkorn U, Herrmann K, Fendler WP

doi: 10.1097/JU.

Uro-Oncology

⁶⁸ Ga-PSMA-PET/CT helps to select patients for salvage radical prostatectomy with local recurrence after primary radiotherapy for prostate cancer

BJU Int.

Pfister D, Haidl F, Nestler T, Verburg F, Schmidt M, Wittersheim M, Steib F, Heidenreich A

doi: 10.1111/bju.15135.

Uro-Oncology

Histological comparison between predictive value of pre-operative 3T multiparametric MRI and ⁶⁸ Ga-PSMA PET/CT scan for pathological outcomes at radical prostatectomy and pelvic lymph node dissection for prostate cancer

BJU Int.

Franklin A, Yaxley WJ, Raveenthiran S, Coughlin G, Gianduzzo T, Kua B, McEwan L, Wong D, Delahunt B, Egevad L, Samaratunga H, Brown N, Parkinson R, Roberts M, Yaxley JW

doi: 10.1111/bju.15134.

Related content

Use of <sup>68</sup> Ga-PSMA PET for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature

18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial

Response assessment using [68Ga]Ga-PSMA ligand PET in patients undergoing systemic therapy for metastatic castration-resistant prostate cancer

The Optimal Timing for PSMA PET/CT in Patients with Biochemical Recurrence After Radical Prostatectomy

PRIMARY Trial - A prospective multi-centre cross-sectional study of the additive diagnostic value of gallium-68 prostate specific membrane antigen (PSMA) PET/CT to multiparametric (mp) MRI in the diagnostic setting for men being investigated for prostate cancer: clinical trial protocol

Preliminary results of a 68 Ga-PSMA PET/CT prospective study in prostate cancer patients with occult recurrence: Diagnostic performance and impact on therapeutic decision-making

68Ga-PSMA-11 PET Detects Residual Prostate Cancer after Prostatectomy in a Multicenter Retrospective Study

68 Ga-PSMA-PET/CT helps to select patients for salvage radical prostatectomy with local recurrence after primary radiotherapy for prostate cancer

Histological comparison between predictive value of pre-operative 3T multiparametric MRI and 68 Ga-PSMA PET/CT scan for pathological outcomes at radical prostatectomy and pelvic lymph node dissection for prostate cancer

¹⁸F-fluciclovine PET-CT and ⁶⁸Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial

Response assessment using [⁶⁸Ga]Ga-PSMA ligand PET in patients undergoing systemic therapy for metastatic castration-resistant prostate cancer

Preliminary results of a ⁶⁸ Ga-PSMA PET/CT prospective study in prostate cancer patients with occult recurrence: Diagnostic performance and impact on therapeutic decision-making

⁶⁸Ga-PSMA-11 PET Detects Residual Prostate Cancer after Prostatectomy in a Multicenter Retrospective Study

⁶⁸ Ga-PSMA-PET/CT helps to select patients for salvage radical prostatectomy with local recurrence after primary radiotherapy for prostate cancer

Histological comparison between predictive value of pre-operative 3T multiparametric MRI and ⁶⁸ Ga-PSMA PET/CT scan for pathological outcomes at radical prostatectomy and pelvic lymph node dissection for prostate cancer